Filtered by tag "Medical Marijuana"

Increase in U.S. Cannabis Consumption Rate

  Since 2011, more than 7.5 million adults have joined the ranks of now 22.4 million regular cannabis users. New Frontier Data’s research suggests that the increase reflects a shift: Infrequent users are consuming more regularly, rather than new consumers suddenly becoming regular users. The growing base of regular consumers highlights the need to understand […]
Read more

Know the Risks: Valuations in the Cannabis Marketplace

By Andrew Lines, MAI, Principal Valuations within the growing cannabis industry don’t always seem to be consistent with operator or investor expectations; this can be due to lack of available transaction data, or misinterpretation of perceived risks – CohnReznick’s Valuation Advisory group can help identify how these risks should be quantified. With regards to Real […]
Read more

Turning Over a New Cannabis Leaf in New York?

By J.J. McCoy, Senior Managing Editor for New Frontier Data It has been some time coming for New York’s state of mind to open up to the medical and market potentials for cannabis, but the nation’s third-largest population (and the financial and cultural crucibles within the country’s largest city) now seems poised to participate in earnest. […]
Read more

Rohrabacher-Blumenauer: What Are The Stakes – Revisited

By J.J. McCoy, Senior Managing Editor for New Frontier Data In what has become a de facto annual event on Capitol Hill (where a version was first proposed in 2001, finally passed in 2014, and renewed each fiscal year since), the Rohrabacher-Blumenauer amendment was again blowing in the wind for the past week amid all the […]
Read more

2 Million Medical Patients Impacted?

  The Rohrabacher-Blumenauer Amendment works to protect medical cannabis programs in 29 states and the District of Columbia. The states most affected by a non-renewal of this amendment would be California, Michigan, and Arizona, as they comprise 70% of the nearly 2 million registered U.S. cannabis patients in the U.S. Support for medical cannabis is […]
Read more

How Final Tax Reforms Impact Your Cannabis Business

By Selvan Boominathan, JD, LLM The Tax Cuts and Jobs Act (TCJA) has become the law of the land, and yet, still no relief for cannabis businesses from Section 280E.  As we wrote in an earlier post, there are still significant tax reductions available to cannabis taxpayers, if you know where to look.  This post […]
Read more

WHO to DOJ, re: CBD: It’s All (Medicinally) Good

By J.J. McCoy, Senior Managing Editor for New Frontier Data Newly published findings from the World Health Organization (WHO) about the medicinal benefits of cannabidiol (CBD) fall in direct opposition to the stance of the U.S. federal government’s keeping it listed as a Schedule I controlled substance. Publishing recent findings which directly contradict both the established […]
Read more

DOJ Rescinds Cole Memo, Raising Stakes for Rohrabacher-Blumenauer Renewal

By J.J. McCoy, Senior Managing Editor for New Frontier Data In a three-paragraph memo released on Thursday, U.S. Attorney General Jeff Sessions rescinded several Obama-era directives which since 2013 had discouraged enforcement of federal marijuana laws in states which had legalized cannabis. Sessions encouraged federal prosecutors to use their own discretion — given the department’s limited [...]
Read more

Alaska’s New Year’s Resolution: To Decide About Onsite Consumption

By J.J. McCoy, Senior Managing Editor for New Frontier Data Were Santa to try and find some medical cannabis to help treat his lower back after completion of his Christmas rounds, a dispensary in Denali, Alaska, would be the closest location from North Pole, Alaska (2016 population: 2,232). But it would be no surprise: It was […]
Read more

Cost Segregation and Cannabis Business Owned Real Estate

By Derek Weaver, Senior Manager As discussed two weeks ago, 280E continues to be a major problem for plant-touching businesses. However, there are several opportunities to minimize taxes and maximize cash flow for ancillary businesses that serve the cannabis industry. This week we will take a look at cost segregation and the benefits for real […]
Read more
Top